Hemab Therapeutics (NASDAQ:COAG) Stock Rating Upgraded by The Goldman Sachs Group

Hemab Therapeutics (NASDAQ:COAG) was upgraded by research analysts at The Goldman Sachs Group to a “strong-buy” rating in a report issued on Tuesday,Zacks.com reports.

COAG has been the subject of several other research reports. Wedbush started coverage on Hemab Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $42.00 price objective for the company. Jefferies Financial Group initiated coverage on shares of Hemab Therapeutics in a report on Tuesday. They issued a “buy” rating and a $39.00 target price on the stock. Wall Street Zen upgraded shares of Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th. Finally, Evercore assumed coverage on shares of Hemab Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $50.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating and two have issued a Buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Strong Buy” and a consensus target price of $41.75.

Hemab Therapeutics Stock Up 7.5%

Shares of NASDAQ:COAG opened at $27.84 on Tuesday. Hemab Therapeutics has a 1 year low of $23.00 and a 1 year high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last announced its quarterly earnings data on Thursday, May 21st. The company reported ($23.98) earnings per share for the quarter.

Insider Buying and Selling at Hemab Therapeutics

In related news, major shareholder Ra Capital Management, L.P. acquired 3,802 shares of Hemab Therapeutics stock in a transaction dated Tuesday, May 19th. The stock was acquired at an average price of $24.97 per share, for a total transaction of $94,935.94. Following the transaction, the insider owned 6,375,972 shares of the company’s stock, valued at $159,208,020.84. This represents a 0.06% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In the last ninety days, insiders have purchased 2,902,872 shares of company stock worth $53,769,784.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.